Entera Bio Ltd (NASDAQ:ENTX) stock rallied Tuesday it has entered into a research collaboration and license agreement with Amgen Inc (NASDAQ:AMGN) in inflammatory disease and other serious illnesses. Entera said it will use its proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen has the option to select up to two additional programs to include in the collaboration with Entera.
Entera stock soared 44.3% to $7.20 in premarket trade. Amgen shares added 1.1% to $196.20.
CalAmp Corp (NASDAQ:CAMP) shares slumped because of supply disruptions in its program to transition to facilities outside China given the trade tensions with the United States. CalAmp said it experienced disruptions because of this transition, along with extended lead times driven by component shortages. This resulted in inbound product supply delays at quarter end and impacted the company's ability to ship certain products to meet customer demand, it said. These supply chain challenges, coupled with macroeconomic factors, have heightened near-term uncertainty, CalAmp added.
Shares of CalAmp sank 11.4% to $15.05.
READ: Stitch Fix shares plunge after missing Wall Street's fiscal 4Q revenue forecast and client target
Stitch Fix Inc (NASDAQ:SFIX) stock tumbled after user growth for the online apparel company fell short of market expectations. The fashion service said it reached 2.9 million active clients in the first fiscal quarter, short of market expectations of 2.95 million. Stitch Fix said it does not expect to benefit from the holiday quarter because shoppers are focusing on buying gifts for others than for themselves. The company is a subscription-based styling service, mailing customers apparel and accessories selected for them by a personal stylist.
Stitch Fix shares dropped almost 19.8% to $20.84.
DSW Inc (NYSE:DSW) stock vaulted higher after reporting strong earnings and guidance in its third-quarter report. The shoe company reported third-quarter revenue increased 17.2% to $833 million; while comparable store sales increased 7.3%. Revenue for the first nine months climbed 12.2% to $2.3 billion.
DSW raised its full-year outlook for adjusted EPS in the range of $1.70 to $1.85 per diluted share, compared to its previous guidance of a range of $1.60 to $1.75 per diluted share.
DSW shares surged 14.4% to $26.47.
Contact Rene Pastor by rene.pastor@proactiveinvestors.com